BioSpace News Archive

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Present DERMAdoctor Eczema Treatment as QVC ® On-Air Guest.

Reata Pharmaceuticals, Inc. today announced financial results for the quarter and full year ended on December 31, 2021 and provided an update on the Company’s business operations and clinical development programs.

eTheRNA immunotherapies NV (‘eTheRNA’), an mRNA technology discovery and development company with a full platform of integrated capabilities, today announced that it will host a key opinion leader (KOL) webinar on mRNA-lipid nanoparticles (LNP) for cancer immunotherapy on Wednesday, March 2, 2022 at 10am ET / 3pm GMT / 4pm CET.

Chimerix announced that Mike Sherman, Chief Executive Officer and Mike Andriole, Chief Financial and Business Officer, will participate in a fireside chat at the Cowen and Company 42nd Annual Health Care Conference on Monday, March 7, 2022 at 12:50 p.m. ET.

InspireMD, Inc. today announced its CGuard Carotid Stent, utilizing its proprietary MicroNet mesh, will be included as a device option for stenting in the CREST-2 Trial.

Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D., as Chief Scientific Officer.

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical stage company, announced that it had dosed the first patient with LNK01001 in its Phase II clinical trial on subjects with atopic dermatitis (AD).

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate in two upcoming investor conferences.

Supira Medical, Inc., a Shifamed portfolio company that is focused on developing a next-generation solution for temporary mechanical circulatory support, announced the closing of $30M in Series C financing.

Goldfinch Bio today announced positive preliminary data from its ongoing Phase 2 clinical trial evaluating GFB-887, a podocyte-targeting small molecule inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), for the treatment of FSGS and diabetic nephropathy (DN).